445012-62-4

Basic information

• Product Name: 4-(Pyridin-3-yl)benzene-1,2-diaMine
• Synonyms: 4-(Pyridin-3-yl)benzene-1,2-diaMine
• CAS NO: 445012-62-4
• Molecular Formula: C₁₁H₁₁N₃
• Molecular Weight: 185.22514
• Mol File: 445012-62-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 398.0±32.0 °C(Predicted)
• Appearance: /
• Density: 1.214±0.06 g/cm3(Predicted)
• PKA: 4.57±0.12(Predicted)
• CAS DataBase Reference: 4-(Pyridin-3-yl)benzene-1,2-diaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Pyridin-3-yl)benzene-1,2-diaMine(445012-62-4)
• EPA Substance Registry System: 4-(Pyridin-3-yl)benzene-1,2-diaMine(445012-62-4)

Safety Data

• Hazardous Substances Data: 445012-62-4(Hazardous Substances Data)

Upstream product

• 167959-19-5 2-nitro-4-(pyridin-3-yl)benzenamine 
• 875-51-4 4-Bromo-2-nitroaniline 
• 88-74-4 2-nitro-aniline 
• 1008-88-4 3-phenylpyridine 
• 82261-42-5 4-pyridin-3-ylaniline 
• 154164-35-9 N-(4-(pyridin-3-yl)phenyl)acetamide 
• 4282-46-6 3-(4'-nitrophenyl)pyridine 
• 154164-36-0 4-(3-pyridyl)acetanilide 
• 1692-25-7 3-pyridylboronic acid 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 

Downstream Products

• 1078728-26-3 C₂₅H₂₃N₃O₃ 

Relevant articles and documents

Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-abelson kinase including the T315i mutant

The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant Bcr-Abl kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type Bcr-Abl and the T315I mutant with IC50 values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant Bcr-Abl.

Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists

Syntheses and structure-activity relationships of a novel class of 2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists are described. Optimization of the lead compound 2a by incorporating substituents into the 5-position or into both the 5- and 6-positions of the benzimidazole core part led to the identification of 5-(5-methyl-1,2,4-oxadiazol-2-yl)benzimidazole (2r: IC50 = 3.3 nM) and 5-(2-methyltetrazol-5-yl)benzimidazole (2u: IC50 = 5.9 nM), both of which are potent, selective, and orally bioavailable Y5 receptor antagonists. Crown Copyright

Gyrase inhibitors and uses thereof

The present invention relates to compounds of the formula I: or a pharmaceutically acceptable derivative or prodrug thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating ba